Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.

ABSTRACT:

Background

The availability of a dual sodium glucose co-transporter 2/dipeptidyl peptidase-4 inhibitor combination in a single-tablet combination (STC) represents a new therapeutic option for patients with type 2 diabetes. Empagliflozin/linagliptin STC has been recently approved by the US Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).

Aim

The aim of this study was to describe the latest clinical evidence on the efficacy and safety profiles of empagliflozin/linagliptin STCs in comparison with the individual components. Juxtaposition of the STC with dapagliflozin/saxagliptin combination was also presented.

Results

Empagliflozin/linagliptin STC given as initial therapy or on metformin background lowered mean glycated haemoglobin (HbA1c

SUBMITTER: Woo V 

PROVIDER: S-EPMC5049636 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature